<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103764</url>
  </required_header>
  <id_info>
    <org_study_id>DSG-SIAUB</org_study_id>
    <nct_id>NCT02103764</nct_id>
  </id_info>
  <brief_title>Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB</brief_title>
  <acronym>SI-AUB-RCT</acronym>
  <official_title>The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the present study is to determine the effectiveness of cyclic desogestrel
      (DSG) compared with cyclic medroxyprogesterone acetate for the treatment of anovulatory
      dysfunctional uterine bleeding (DUB) in the following aspects:

        1. Endometrial histopathology changes

        2. Menstrual cycle control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anovulatory dysfunctional uterine bleeding (DUB) is the most common cause of abnormal uterine
      bleeding especially in postmenarcheal adolescent, perimenopausal women, patient with
      polycystic ovary syndrome (PCOS) and in obese women. Aims of treatment in women with
      anovulatory DUB are to restore the natural control mechanism of endometrium (introduce normal
      synchronous growth, development, shedding of a structural stable endometrium) and to prevent
      endometrial hyperplasia. The two main treatment options are estrogen-progestin therapy and
      progestin therapy. Women who are sexually active and not immediately prepared to pursue
      pregnancy are best manage by estrogen-progestin treatment especially combined oral
      contraceptive pills (COCs) but in perimenopausal women, obese women or women who can't
      tolerate COCs or have contraindications in using COCs, cyclic progestin will be the treatment
      of choice. Common used progestin in anovulatory DUB is medroxyprogesterone acetate (MPA) 5-10
      mg/day for 10-14 days each month. This progestin has strong progestogenic effect but has some
      undesirable effect such as glucocorticoid effect, mineralocorticoid effect and androgenic
      effect. Long term using this progestin especially in obese women or perimenopausal women who
      have risk for diabetes mellitus and dyslipidemia may be negative effect to glucose and lipid
      metabolism. DSG is the third generation progestin with no glucocorticoid, mineralocorticoid
      effect and low androgenic effect may be the better choice of treatment but the data of DSG in
      treatment of anovulatory DUB us scanty. So this study will evaluate the effect of cyclic DSG
      in endometrial histology changing and lipid, glucose metabolism in patient with anovulatory
      DUB.

      Comparison : Women with anovulatory DUB are randomized into two groups, receiving a course of
      either cyclic DSG or cyclic MPA. The main outcome measured is to compare the effect of both
      interventions on endometrial histology changing.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in endometrial histology</measure>
    <time_frame>Baseline, Day 8 or 9 or 10 of treatment period in first month</time_frame>
    <description>The participants are evaluated for changing of endometrial histology at day 8 or 9 or 10 of treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of withdrawal bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the occurrence of withdrawal bleeding between cyclic DSG and cyclic MPA after taking each groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of cyclic DSG on lipid metabolism compared with cyclic MPA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of cyclic DSG on glucose metabolism compared with cyclic MPA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At day 8 or 9 or 10 of the first cycle and 3, 6 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dysfunctional Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>Desogestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel</intervention_name>
    <description>Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month</description>
    <arm_group_label>Desogestrel</arm_group_label>
    <other_name>Cerazette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone acetate</intervention_name>
    <description>Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month</description>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
    <other_name>Provera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women with anovular DUB (proved by endometrial histology)

          -  Age &gt; 18 yr.

        Exclusion Criteria:

          -  Any uterine pathology that might cause abnormal uterine bleeding

          -  Contraindication to progestin treatment (such as breast cancer)

          -  Severe drug allergy towards a progestogen

          -  Intake of any hormonal treatment in the previous 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manee Rattanachaiyanont, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manee Rattanachaiyanont, M.D.</last_name>
    <phone>+66-2419-4657</phone>
    <email>manee.rat@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nisarath Soontrapa, M.D.</last_name>
    <phone>+66-8-7936-6457</phone>
    <email>pui_pika@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manee Rattanachaiyanont, M.D.</last_name>
      <phone>+66-2419-4657</phone>
      <email>manee.rat@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Nisarath Soontrapa, M.D.</last_name>
      <phone>+66879366457</phone>
      <email>pui_pika@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Manee Rattanachaiyanont, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>July 4, 2015</last_update_submitted>
  <last_update_submitted_qc>July 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Manee Rattanachaiyanont</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital</investigator_title>
  </responsible_party>
  <keyword>Anovulatory Dysfunctional Uterine Bleeding</keyword>
  <keyword>cyclic desogestrel</keyword>
  <keyword>cyclic medroxyprogesterone acetate</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>endometrial histology changing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

